Dr. David Berman is Head of Research and Development at Immunocore, a leading T cell receptor biotechnology company. David and his team are working on new therapies that can train the immune system to recognize and kill cancer. This approach to treating cancer is called immunotherapy. Immunocore is taking a novel approach to immunotherapy by leveraging the mechanisms used by T cell receptors to identify indicators of cancer within cancer cells. Much of David’s time outside of work is spent driving his daughters to their soccer and lacrosse games and watching them play. He also enjoys cycling with his family and thought-provoking solo cycling outings. He received his bachelor’s degree in biology from the Massachusetts Institute of Technology. Afterwards, David was awarded his PhD under the mentorship of Dr. Alfred Gilman (Nobel Prize 1994) and his MD from the University of Texas Southwestern Medical Center at Dallas. He completed his Residency in Anatomic Pathology at the National Cancer Institute and a Fellowship in Pathology at The Johns Hopkins University School of Medicine. David then began his 10-year tenure at Bristol-Myers Squibb, where he held various senior development roles in immuno-oncology. He then spent three years in immuno-oncology leadership positions at MedImmune and AstraZeneca. In our interview, David shares more about his life and science.
